Avenue Therapeutics Inc. (ATXI)
$0.52
$0.15
(38.67%)
As on 04-Sep-2026 10:25EDT
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.6 %
-
ROCE
-125.7 %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
3,294,967
9 Years Aggregate
CFO
$-79.21 Mln
EBITDA
$-98.74 Mln
Net Profit
$-84.63 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
| -- | -- | -- | -- | -13.0 | -54.3 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
| 1,117.0 | -86.1 | -84.7 | -38.0 | 77.8 | 48.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
|
0.5 | 1.9 | 0.0 | -2.8 | -- | -229.2 | -- | 3.3 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout Avenue Therapeutics (ATXI)
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the... treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Read more
-
CEO & Director
Dr. Alexandra MacLean M.D.
-
CEO & Director
Dr. Alexandra MacLean M.D.
-
Headquarters
Bay Harbor Islands, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Avenue Therapeutics (ATXI)
What is the current share price of Avenue Therapeutics Inc (ATXI) Today?
The share price of Avenue Therapeutics Inc (ATXI) is $0.52 (NASDAQ) as of 04-Sep-2026 10:25 EDT. Avenue Therapeutics Inc (ATXI) has given a return of -12.96% in the last 3 years.
What is the current PB & PE ratio of Avenue Therapeutics Inc (ATXI)?
Since, TTM earnings of Avenue Therapeutics Inc (ATXI) is negative, P/E ratio is not available.
The P/B ratio of Avenue Therapeutics Inc (ATXI) is 3.34 times as on 27-Aug-2026, a 36 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-0.27 |
1.14 |
2023 |
-0.40 |
2.61 |
2022 |
-0.46 |
0.42 |
2021 |
-0.30 |
0.32 |
What is the 52 Week High and Low of Avenue Therapeutics Inc (ATXI)?
The 52-week high and low of Avenue Therapeutics Inc (ATXI) are Rs 0.52 and Rs 0.52 as of 05-Sep-2026.
What is the market cap of Avenue Therapeutics Inc (ATXI)?
Avenue Therapeutics Inc (ATXI) has a market capitalisation of $ 2 Mln as on 27-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Avenue Therapeutics Inc (ATXI)?
Before investing in Avenue Therapeutics Inc (ATXI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.